Optimizing Frontline ADCs: Sequencing, Targets, and Resistance

Dr. Pedro Barata and Dr. Giuseppe Curigliano discuss the rapid paradigm shift of antibody-drug conjugates into frontline advanced and curative-intent perioperative settings and the clinical challenges of optimal sequencing, target selection, and cross-resistance.

LINK TO FULL TRANSCRIPT